Sulfasalazine + Hydroxychloroquine ( DrugBank: Sulfasalazine, Hydroxychloroquine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05051137 (ClinicalTrials.gov) | January 12, 2006 | 10/9/2021 | Real-World Emulation of the SWEFOT Trial | Comparison of Infliximab With Sulfasalazine/Hydroxychloroquine Initiated After Methotrexate by Rheumatoid Arthritis Patients Treated in Clinical Practice (Real-World Emulation of SWEFOT Trial) | Rheumatoid Arthritis | Biological: Infliximab;Drug: Sulfasalazine + Hydroxychloroquine | Karolinska Institutet | Harvard Medical School | Completed | 18 Years | N/A | All | 509 | Sweden |